Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-04-06FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for escitalopram oxalate from Quallent Pharmaceuticals Health LLC, authorizing a generic version of …
-
FDA approval · 2023-04-03FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved Novadoz Pharmaceuticals LLC's original application for doxepin hydrochloride (generic). The approval supports the generic produ…
-
FDA approval · 2023-03-31FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)
The FDA approved a supplemental application from ScieGen Pharmaceuticals, Inc. for a generic pregabalin product. The approval covers the sam…
-
FDA approval · 2023-03-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA granted supplemental approval for a generic venlafaxine hydrochloride product from Aurobindo Pharma Limited.
-
FDA approval · 2023-03-24FDA Approved: PREGABALIN — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for pregabalin from Solco Healthcare US, LLC under ANDA207883. The drug is indicated for neuropathic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-23FDA Approved: PAROXETINE — Supplemental Application (Modavar Pharmaceuticals LLC)
FDA approved a supplemental application for generic paroxetine filed by Modavar Pharmaceuticals LLC under ANDA212645.
-
FDA approval · 2023-03-15FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for escitalopram oxalate submitted by Exelan Pharmaceuticals Inc.
-
FDA approval · 2023-02-17FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's generic doxepin hydrochloride for oral use under an Original Application (ANDA).
-
FDA approval · 2023-02-16FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for escitalopram oxalate from Amneal Pharmaceuticals LLC, confirming approval of their generic produ…
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study [Phase 3]
An 8-week pilot Phase 3 trial evaluating cannabidiol for anxiety disorders, including generalized anxiety disorder and social anxiety disord…
-
FDA approval · 2023-02-08FDA Approved: DIAZEPAM — Supplemental Application (Natco Pharma USA LLC)
FDA approved Natco Pharma USA LLC's supplemental application for Diazepam (generic) under ANDA210363. This approval advances the generic Dia…
-
FDA approval · 2023-01-31FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for paroxetine from ANI Pharmaceuticals, indicating an approved change to the product (e.g., lab…
-
FDA approval · 2023-01-17FDA Approved: ALPRAZOLAM — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Alprazolam by Par Health USA, LLC. This action likely updates labeling or expands the indica…
-
FDA approval · 2023-01-17FDA Approved: OXAZEPAM — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Oxazepam (generic) submitted by Actavis Pharma, Inc. (ANDA072253).
-
FDA approval · 2023-01-13FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for alprazolam from Mylan Pharmaceuticals Inc., indicating a revised or expanded approval under an N…
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Randomized Trial of Adult Participants With Generalized Anxiety Disorder [Phase 3]
This document reports the completion and posting of results for a Phase 3 randomized trial in adults with Generalized Anxiety Disorder. The …
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for escitalopram oxalate (a generic version of Lexapro), enabling market entry…
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for escitalopram from Macleods Pharmaceuticals Limited, enabling the marketing of their generic …
-
FDA approval · 2022-11-28FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approves the original application for venlafaxine hydrochloride tablets from Rising Pharma Holdings, Inc., making a generic version …
-
FDA approval · 2022-11-23FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA has approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc.
-
FDA approval · 2022-11-21FDA Approved: VENLAFAXINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for venlafaxine submitted by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders [Phase 4]
Phase 4 clinical trial update on psycho-biological substrates of thermal cure for generalized anxiety disorders completed.
-
FDA approval · 2022-08-30FDA Approved: VENLAFAXINE — Original Application (Zydus Lifesciences Limited)
FDA approved the original application (ANDA) for venlafaxine from Zydus Lifesciences Limited, enabling generic access to the antidepressant.
-
FDA approval · 2022-08-15FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) from Viatris Specialty LLC.
-
FDA approval · 2022-08-09FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Venlafaxine Hydrochloride (extended-release) submitted by Chartwell RX, LLC.